Pure Encapsulations

L-Glutamine 850 mg

D
N+ Score64
ProteinServing: 1 Capsule(s)Type: Amino acid/Protein

Pure Encapsulations L-Glutamine 850 mg is a single-ingredient amino acid supplement, offering 850 mg of L-Glutamine per capsule. This product earned an N+ Score of 64, receiving a 'D' grade, which places it in the average tier according to our assessment. The 850 mg dosage of L-Glutamine is listed at a clinical dose, which research suggests may play a role in various bodily processes. The product boasts 100% label transparency, ensuring all ingredient information is clearly disclosed. This supplement may be suitable for individuals who prefer a lower-dose L-Glutamine option or require precise dosing flexibility.

About This Product

L-Glutamine 850 mg by Pure Encapsulations is a protein supplement containing 1 active ingredients. It has earned an N+ Score of 64/100 (Grade D).

This product features a fully transparent label with individual ingredient amounts disclosed, and key ingredients are present at clinically effective doses based on peer-reviewed research.

Notable clinical-dose ingredients include L-Glutamine.

N+ Score Breakdown

Ingredient Adequacy100/100

Are key ingredients present at clinically effective doses based on research?

Formula Completeness0/100

Does the product include all expected ingredients for its supplement category?

Label Transparency100/100

Are individual ingredient amounts clearly disclosed without proprietary blends?

Ingredient Diversity44/100

Does the formula include a breadth of beneficial compounds from multiple pathways?

Strengths

  • +Key ingredients at clinically effective doses
  • +Fully transparent label with individual ingredient amounts disclosed
  • +1 ingredient(s) at clinical dose levels

Weaknesses

  • Missing several expected ingredients for its category

Ingredient Analysis (1 ingredients)

IngredientAmountDose Adequacy
L-Glutamine850.000 mgHigh

Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.